General Updates

July 2, 2026 BSE Limited National Stock Exchange of India Ltd Listing Department- Exchange Plaza, C-1, Block G, Phiroze Jeejeebhoy Tower, Bandra Kurla Complex, Dalal Street, Bandra (E) Mumbai – 400 001, Mumbai – 400 051, Scrip Code- 533543, Symbol: BROOKS Dear Madam/ Sir, Sub: Intimation under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 – Incorporation of Wholly Owned Subsidiary Dear Sir/Madam, Pursuant to Regulation 30 read with Schedule III of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 and the applicable SEBI Circular, we wish to inform you that Brooks Laboratories Limited has incorporated a wholly owned subsidiary in the name of ABRIDGE SPECIALITY LIMITED on 2nd July 2026. The Certificate of Incorporation has been issued by the Ministry of Corporate Affairs on the same day. The requisite details as required under Regulation 30 read with Schedule III of the SEBI Listing Regulations and SEBI Circular No. SEBI/HO/CFD/CFD-PoD-1/P/CIR/2023/123 Dated July 13, 2023, for incorporation of Wholly Owned Subsidiary Company are enclosed herewith as Annexure – A. The above information is also being made available on the website of the Company. Please take the above information on record. Thanking You. For Brooks Laboratories Limited, Krutika Rane Company Secretary and Compliance Office Membership No.: 66310 Annexure A Details required under Regulation 30 read with Schedule III of the Securities and Exchange Board of India (“SEBI") (Listing Obligations and Disclosure Requirements) Regulations, 2015 (“LODR”) and SEBI Circular No. SEBI/HO/CFD/CFD-PoD-1/P/CIR/2023/123 Dated July 13, 2023. Particulars Details Name of the target entity, details in brief such as Abridge Speciality Limited, a newly incorporated wholly size, turnover etc. owned subsidiary is incorporated as a Wholly Owned Subsidiary (WOS) of the Company on 2nd July 2026. Authorised Share Capital: Rs. 1,00,000 (Rupees One Lakh). Turnover/Net worth: Not Applicable, since it is a newly incorporated company and is yet to commence its business operations. Whether the acquisition would fall within Brooks Laboratories Limited, (the ‘Company’/ ‘BLL’) is related party transaction(s) and whether the the promoter of Abridge Speciality Limited (‘ASL’), a promoter/ promoter group/ group companies Wholly Owned Subsidiary. ASL is a Related Party. have any interest in the entity being acquired? If BLL would hold 100% share capital of ASL. yes, nature of interest and details thereof and whether the same is done at “arm’s length”; Industry to which the entity being acquired Manufacturing and Marketing of Pharmaceuticals and belongs related products. Objects and impact of acquisition (including but The incorporation of WOS aligns with the Company's not limited to, disclosure of reasons for strategic objective to expand its business. acquisition of target entity, if its business is outside the main line of business of the listed entity); Brief details of any governmental or regulatory Not Applicable. approvals required for the acquisition/incorporation; Indicative time period for completion of the Not Applicable. acquisition/incorporation. Nature of Consideration - whether cash The initial share capital subscribed at the time of consideration or share swap or any other form Incorporation issued at face value. and details of the same; Percentage of shareholding / control acquired 100% and / or number of shares acquired Brief background about the entity acquired in Abridge Speciality Limited is recently incorporated and it terms of products/line of business acquired, date is yet to commence its business. Therefore, the history of of incorporation, history of last 3 years turnover, the last 3 years turnover is not available. country in which the acquired entity has presence and any other significant information (in brief);